

PRESS RELEASE

YMC acquires Zurich based ChromaCon business

YMC expands footprint in multi-column continuous purification technologies with additional investment in Asia planned for 2019

Kyoto, Japan; Zurich, Switzerland; 9 Apr., 2019 – YMC acquires ChromaCon AG – a leader in continuous chromatography.

YMC Co., Ltd. ("YMC"), a leading supplier of separation resins, services and systems for the pharmaceutical market, has acquired all shares in ChromaCon AG (Zurich, Switzerland) and executed the transfer of 100% shares in the Company on April 1, 2019.

ChromaCon has a portfolio of proprietary continuous chromatography technologies and markets laboratory scale separation/purification systems utilizing these technologies globally. ChromaCon technology has pioneered twin-column purification that drastically increases productivity in both large (biopharmaceutical) and small (pharmaceutical) molecule manufacturing as well as significantly reduces operational cost.

YMC and ChromaCon have already built and maintained a strategic business alliance with YMC being an exclusive distributor of ChromaCon's lab-scale systems in Japan and India. ChromaCon had also licensed technologies to YMC Process Technologies ("YPT") (Devens MA, USA) for GMP production scale equipment. YMC completed its acquisition of YPT from LEWA-Nikkiso America December 2018. YPT develops and manufactures scale-up separation systems for the pharmaceutical manufacturing industry.

With ChromaCon joining the YMC Group, YMC has now a fully integrated organization (YMC, ChromaCon and YPT) leading the development and commercialization of continuous separation/purification systems for biopharmaceutical and pharmaceutical industry from lab to production scale (GMP) manufacturing.

Moreover, the YMC Group provides a range of chromatography resins, columns and services which enable manufacturers to access a full complement of resources to facilitate the cost-effective production of next generation drugs.

Extending its present global leadership role in continuous separation/purification technology the YMC Group is furthering its investment through expanding R&D of the continuous separation/purification platform in its Kyoto, Japan, site where YMC is building a new facility, scheduled to start operations in October 2019.



The YMC Group intends to accelerate development of the continuous separation/purification business on a global basis leveraging the YMC Japan, US, & EU sites in a quest to lead innovation in continuous separation/purification system business in all geographies.

- ENDS -

About ChromaCon AG



ChromaCon is a life science tool company located at Zurich, Switzerland, providing best-in-class process solutions to the pharmaceutical industry. ChromaCon has developed and patented novel process principles, process control and simulation software, equipment designs and operating software for batch, cyclic and continuous chromatography. These process solutions result in significant CAPEX and OPEX cost savings and enabling scalable chromatographic solutions for large scale purification applications. The Contichrom laboratory-scale equipment is co-marketed worldwide by the ChromaCon and its partners. ChromaCon has provided global licenses for its process technologies to YPT for implementation into scale-up systems.

web: www.chromacon.com

About YMC Co., Ltd.



YMC is a private life science company headquartered in Kyoto, Japan. Founded in 1980, YMC has over 9 affiliates and facilities throughout Asia, Europe and America. The about 500 employees are providing best-in-class lab and process solutions to pharmaceutical industry. YMC focus is in innovation, production and sales of packing materials, packed columns and systems for High Performance Liquid Chromatography (HPLC), Low Pressure Liquid Chromatography (LPLC) and custom purification and custom synthesis. YMC operates a CMO facility and pilot plant incorporating state of the art simulated moving bed (SMB) purification. YMC is also engaged in the production and sales of micro-reactor systems. YMC's intellectual properties, cultivated from many years of experience, will continue to push



the limits to create a prosperous future for purification and discovery of small and large molecule therapies.

YMC Contact

Corporate Strategy Dept.: Nakabayashi, h-nakabayashi@ymc.co.jp,

Tel: +81-75-342-4510 Fax: +81-75-342-4511

web: www.ymc.co.jp

9 April 2019